Immunome, Inc. · NASDAQ:IMNM
Immunome — Investor Presentation (November 2022)
35 slides from Immunome's investor presentation, Nov 15, 2022
Slide 1: Harnessing the Power of the Human Memory B Cell
Harnessing the Power of the Human Memory B Cell November 15, 2022 Immunome, Inc. 665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com Copyright © 2022 Immunome, Inc. All rights reserved.
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements This presentation includes certain disclosures that contain “forward-looking statements” All statements contained in this presentation are made as of the date specified on the intended to qualify for the “safe harbor” from liability established by the Priva
Slide 3: Immunome "At a Glance"
Immunome “At a Glance” INFECTIOUS DISEASES Reveals How the Human B Cell Sees Disease in its IMM-BCP-01 Treatment of COVID-19 in Clinical Testing Topline Data • Topline safety and PK data expected by the end of 2022 1Q 2023 Natural State • Results to be reported 1Q 2023 • Current therapies are limite
Slide 4: Human Immune System – Untapped Source for Therapeutic Antibodies
Human Immune System – Untapped Source for Therapeutic Antibodies Mounting Evidence in Literature for Using Patient-derived Antibodies1 Tumor cells CD4+ CD8+ T cell Antibody-Based Therapies Represent A Large T cell IFNg IL-12 Market Across Disease Indications2 TCR MHC II MHC I BCR Antigen presentatio
Slide 5: We See the Disease Through the Lens of a Memory B-cell
We See the Disease Through the Lens of a Memory B-cell Interrogate Most Educated Components of Immune Response in an Unbiased Manner at Industrial Scale Multiple Patients Blood, Lymph nodes Ongoing access to new and diverse patient memory B cells and tumor tissue Immortalizing B-cell Response Propri
Slide 6: Immunome Development Pipeline
Immunome Development Pipeline INFECTIOUS PRODUCT CANDIDATE ANTICIPATED DISEASES TARGET DESCRIPTION DISCOVERY PRECLINICAL PHASE 1B MILESTONE Three SARS- Three antibody Topline Data IMM-BCP-01 CoV-2 Epitopes cocktail 1Q 2023 PRODUCT CANDIDATE ANTICIPATED ONCOLOGY TARGET DESCRIPTION DISCOVERY PRECLINIC
Slide 7: Infectious Diseases: IMM-BCP-01
Infectious Diseases: IMM-BCP-01 Collaboration with U.S. DoD & DHA for IMM-BCP-01 Program, Awarded Up to $17.6M in Funding* * OTA: W911QY-20-9-0019 Copyright © 2022 Immunome, Inc. All rights reserved.
Slide 8: IMM-BCP-01: Three Antibody Cocktail for the Treatment of COVID-19
IMM-BCP-01: Three Antibody Cocktail for the Treatment of COVID-19 IMM-BCP-01 three In vitro preclinical In vitro neutralization Identified Antibodies from antibody cocktail designed neutralization of variants translates into in vivo SARS-CoV-2 patient to retain efficacy against that have emerged eff
Slide 9: Emerging Variants Shape the COVID Antibody Market
Emerging Variants Shape the COVID Antibody Market Variant 120 Alpha Beta Gamma EUA Granted ? Delta LLY6 100 Omicron BA.1 Omicron BA.2 AZ5 Omicron BA.4 Omicron BA.5 GSK/VIR4 80 Omicron BA.2.12.1 MUTATIONS Omicron BA.2.75 LLY3 Omicron BQ.1 REGN2 60 Omicron XBB LLY1 1. Bamlanivimab (https://www. fda.go
Slide 10: IMM-BCP-01 Neutralizes Virus Utilizing Different Mechanisms
IMM-BCP-01 Neutralizes Virus Utilizing Different Mechanisms ANTIBODY INDUCED CONFORMATIONAL CHANGE DESTABILIZES SPIKE PROTEIN* Structural analysis demonstrates IMM20253 binding 2 induces unfolding of spike trimer • Increasing antibody:trimer ratio results in dissociation of IMM20253 trimer into solu
Slide 11: IMM-BCP-01 Also Induces Multiple Viral Clearance Mechanisms In Vitro
IMM-BCP-01 Also Induces Multiple Viral Clearance Mechanisms In Vitro Viral Clearance Mechanisms are Critical to Therapeutic Efficacy Loss of Fc Driven Effector Function In Vitro Data Shows Potential for Multiple Viral Decreases In Vivo Activity Clearance Mechanisms In Vivo Literature demonstrates th
Slide 12: IMM-BCP-01 Continues to be Active Against the Omicron Variants
IMM-BCP-01 Continues to be Active Against the Omicron Variants In vitro Neutralization of Omicron BA.1 and In vitro Neutralization Translates into Robust BA.2 in Live Virus Testing1 Viral Load Reduction in Hamster Model2 Omicron BA.1 Cmax2 Log [Ab], nM Vehicle IMM-BCP-012 1. Nikitin et al Sci Immuno
Slide 13: IMM-BCP-01: Poised to Be a Critical Player in the Management of the Pandemic
IMM-BCP-01: Poised to Be a Critical Player in the Management of the Pandemic Phase 1b Topline data 1Q 2023 SELECT DIMENSIONS PANDEMIC RESPONSE NEEDS IMM-BCP-01 ADVANTAGES Pre-clinical efficacy against all CDC variants of EMERGING VARIANTS New variants evade existing therapies concern tested to date*
Slide 14: Oncology
Oncology Copyright © 2022 Immunome, Inc. All rights reserved.
Slide 15: B cells: Critical Players in Tumor Immunity
B cells: Critical Players in Tumor Immunity B Cells T Cells Macrophages Dendritic Cells Survival in Melanoma patients • B cell infiltration more closely associated with survival than T cell presence in multiple cancers • Success of IO therapies appears to be associated with coordinated response incl
Slide 16: Leveraging Memory B Cell Responses to Uncover Untapped Biology and Novel Therapeutic Targets
Leveraging Memory HER2 B Cell Responses to TROP2 Uncover Untapped EGFR Biology and Novel Therapeutic Targets CD20 Canonical CD19 Current Therapies are Based on a Limited Knowledge of the Novel targets have the potential to Diversity and Complexity lead to more effective antibody and Non-Canonical wi
Slide 17: Actionable Targets Across Cancer-Relevant Processes
Actionable Targets Across Cancer-Relevant Processes Antibodies identified to date define Immune functionally relevant clusters: Modulation Novel • Cluster around distinct areas of target-rich Targets Discovery biology Extracellular Engine Matrix • Biological clusters are patient-independent • Antibo
Slide 18: Immunome Oncology R&D Pipeline
Immunome Oncology R&D Pipeline Targets Identified from Authentic Human Immune Response Program Novel Immune Modulators Potential Cancers of Relevance Format IMM-ONC-01 Neutralize IL-38; recruit and activate immune cells Squamous carcinomas of lung, head & neck, mAb (Anti-IL-38) gastroesophageal Targ
Slide 19: IMM-ONC-01 Anti IL-38 Antibody
IMM-ONC-01 Anti IL-38 Antibody Copyright © 2022 Immunome, Inc. All rights reserved.
Slide 20: Growing Evidence of IL-38 as a Key Immune Modulator
Growing Evidence of IL-38 as a Key Immune Modulator Takeda et al. PLoS One (2017) Copyright © 2022 Immunome, Inc. All rights reserved. 20
Slide 21: IMM-ONC-01 Anti IL-38 Antibody
IMM-ONC-01 Anti IL-38 Antibody Anti IL-38 Antibody Therapy has Potential to Be an Important Advancement in Cancer Care IL-38 Appears to Suppress Anti-Tumor Immunity IL-38, a novel cancer Blocking IL-38 leads IL-38 dampens to tumor control in IND filing target, identified by immune response to head &
Slide 22: IL-38 Expression in Solid Tumors
log2TPM log2TPM 25% 23% Bladder Head & Neck Skin 53% 14% Esophagus 30% (% of Patient Expression) Prostate 41% *Cancer Genome Atlas (TCGA) data from Firehouse Legacy dataset Lung, Squamous IL-38 Expression in Solid Tumors IL-38 is Expressed in Multiple Tumors 9% Tumor versus Healthy Adjacent Tissue E
Slide 23: IL-38 Expression is Associated with Reduced Immune Cell Infiltration
IL-38 Expression is Associated with Reduced Immune Cell Infiltration IL-38 Overexpression Inhibits Infiltration High IL-38 Expression is Associated with of T cells into Tumors In Vivo Reduced Immune Cell Infiltration* • IL-38 high tumor samples correlate with reduced infiltration of multiple immune
Slide 24: Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models
IMM-ONC-01 Anti IL-38 Antibody Blocking IL-38 Leads to Tumor Control in Two Different Tumor Models* Demonstration of Anti-Tumor Activity Induction of Anti-Tumor Memory (B16F10 Model) (EMT6 Model) • Immunologically cold tumor model • ~40% response rate upon treatment with IMM-ONC-01 • IMM-ONC-01 sign
Slide 25: IL-38 and Potential Combinations
IL-38 and Potential Combinations Mechanistic Rationales for Both Chemotherapy and Immune Checkpoint Combinations Tumor Cells Can Secrete IL-38 Upon IL-38 Levels Correlate with PD-L1 Apoptosis Induction Expression • IL-38 secretion associated with apoptotic cell death1 • Acts during tissue damage to
Slide 26: IMM-ONC-01 Program Summary
IMM-ONC-01 Program Summary A Novel Antibody Targeting IL-38 • IL-38 is a member of the IL-1 family of cytokines • Preclinical research confirms the mechanism of action and demonstrates efficacy of IMM-ONC-01 as a monotherapy • Gene expression profiling of patient tumors suggest normal IL-38 biology
Slide 27: Oncology Platform and Research Pipeline
ONCOLOGY Platform and Research Pipeline Copyright © 2022 Immunome, Inc. All rights reserved.
Slide 28: Platform Maps Diverse Memory B-cell Repertoire Against Cancer
Platform Maps Diverse Memory B-cell Repertoire Against Cancer Highly Productive Platform Operating at Industrial Scale CANCER TYPES INTERROGATED Diverse Cancer Landscape Other 12% 14 >350 ~140 ~250K Renal 7% Breast 38% H&N 9% Cancers Patients Libraries Hybridoma Lung 13% *Source tissues include LN,
Slide 29: Discovery Engine Identified Multiple Processes Driving Cancer Progression
Discovery Engine Identified Multiple Processes Driving Cancer Progression 1. Membrane Dynamics/Exosomes Elevated cell motility associated invasion and metastasis • IMM20059 (anti EPN1 antibody) 2. Metabolism Immune Modulation High demand for materials supporting rapid tumor expansion Novel Targets 3
Slide 30: Discovery Engine Also Identified Multiple Target Features
Discovery Engine Also Identified Multiple Target Features Several Proteins Ectopically (Abnormally) Expressed On Cancer Cells – Multiple ADC Targets Across Clusters Targeting Unique Features on Cancer Cells Diverse B Cell Clones Applicable Across Broad Cancer Indications NORMAL CANCER Ectopic expres
Slide 31: IMM20059 Anti-EPN1 Antibody
IMM20059 Anti-EPN1 Antibody Preclinical antibody program targeting ectopically expressed protein EPN1, a novel EPN1 ectopically Impact of targeting cancer expressed on surface ectopic EPN1: Preclinical efficacy target, identified by of cancer cells and H&N cancer patient Mechanism of Action testing
Slide 32: IMM20059 Binds to EPN1 on Cell Surface
IMM20059 Binds to EPN1 on Cell Surface EPN1 Ectopically Expressed on Tumor Cells EPN1 Regulates Trafficking of Cell Surface IMM20059 Binds to EPN1 on Cell Surface Receptors • EPN1 known to bind intracellular domains of • Identified EPN1 as the target of patient-derived receptors linked to cancer ant
Slide 33: Targeting EPN1 in Combination with PD-L1 Enhances Anti-Tumor Efficacy
Targeting EPN1 in Combination with PD-L1 Enhances Anti-Tumor Efficacy Tumor Growth Anti-tumor Immune Response • Combination of IMM20059 + atezolizumab leads • IMM20059 + atezolizumab treatment of B16.F10 to significant tumor control in the B16.F10 model tumor-bearing mice leads to upregulation of as
Slide 34: Intellectual Property Portfolio & Strategy
Intellectual Property Portfolio & Strategy Platform technology and discovery engine protected through base patents and know-how exclusively-licensed by Immunome and further patents and trade secrets owned by Immunome Antibodies targeting SARS-CoV-2 epitopes and 2 or 3-antibody cocktails covered by I
Slide 35: Immunome "At a Glance"
Immunome “At a Glance” INFECTIOUS DISEASES Reveals How the Human B Cell Sees Disease in its IMM-BCP-01 Treatment of COVID-19 in Clinical Testing Topline Data • Topline safety and PK data expected by the end of 2022 1Q 2023 Natural State • Results to be reported 1Q 2023 • Current therapies are limite